Lipocine Inc. Files Q3 2024 10-Q Report
Ticker: LPCN · Form: 10-Q · Filed: 2024-11-07T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceutical
TL;DR
Lipocine's Q3 2024 10-Q is in. Check financials.
AI Summary
Lipocine Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial performance and operational updates for the third quarter of 2024. Specific financial figures and operational highlights are presented within the report.
Why It Matters
This filing provides investors with the latest financial and operational status of Lipocine Inc., crucial for understanding the company's trajectory in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Lipocine faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- Q3 2024 — Reporting Period (The third quarter of 2024, for which financial results are reported.)
- 2024-09-30 — Period End Date (The specific date marking the end of the reporting quarter.)
- 2024-11-07 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)
Key Players & Entities
- Lipocine Inc. (company) — Filer of the 10-Q report
- 20240930 (date) — End of the reporting period
- 20241107 (date) — Filing date of the report
- SALT LAKE CITY (location) — Company's business and mailing address city
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is for the quarter ended September 30, 2024.
When was this 10-Q report filed with the SEC?
This 10-Q report was filed on November 7, 2024.
What is the company's primary industry classification?
Lipocine Inc. is classified under Pharmaceutical Preparations (SIC code 2834).
Where is Lipocine Inc. located?
Lipocine Inc.'s business and mailing address is in Salt Lake City, Utah.
What was the previous fiscal year end date mentioned?
The previous fiscal year end date mentioned is December 31, 2023.
From the Filing
0001493152-24-043893.txt : 20241107 0001493152-24-043893.hdr.sgml : 20241107 20241107060910 ACCESSION NUMBER: 0001493152-24-043893 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 69 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241107 DATE AS OF CHANGE: 20241107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 241432911 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 10-Q 1 form10-q.htm false --12-31 Q3 0001535955 P10Y 0001535955 2024-01-01 2024-09-30 0001535955 2024-11-06 0001535955 2024-09-30 0001535955 2023-12-31 0001535955 2024-07-01 2024-09-30 0001535955 2023-07-01 2023-09-30 0001535955 2023-01-01 2023-09-30 0001535955 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-06-30 0001535955 us-gaap:CommonStockMember 2023-06-30 0001535955 us-gaap:TreasuryStockCommonMember 2023-06-30 0001535955 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001535955 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001535955 us-gaap:RetainedEarningsMember 2023-06-30 0001535955 2023-06-30 0001535955 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001535955 us-gaap:CommonStockMember 2022-12-31 0001535955 us-gaap:TreasuryStockCommonMember 2022-12-31 0001535955 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001535955 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001535955 us-gaap:RetainedEarningsMember 2022-12-31 0001535955 2022-12-31 0001535955 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-06-30 0001535955 us-gaap:CommonStockMember 2024-06-30 0001535955 us-gaap:TreasuryStockCommonMember 2024-06-30 0001535955 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001535955 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001535955 us-gaap:RetainedEarningsMember 2024-06-30 0001535955 2024-06-30 0001535955 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-12-31 0001535955 us-gaap:CommonStockMember 2023-12-31 0001535955 us-gaap:TreasuryStockCommonMember 2023-12-31 0001535955 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001535955 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001535955 us-gaap:RetainedEarningsMember 2023-12-31 0001535955 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-07-01 2023-09-30 0001535955 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001535955 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0001535955 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001535955 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001535955 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001535955 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-09-30 0001535955 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001535955 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-09-30 0001535955 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001535955 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001535955 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001535955 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-07-01 2024-09-30 0001535955 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001535955 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0001535955 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001535955 us-gaap:AccumulatedOtherComprehe